Aptera Motors Raises $6M at $1.75, Warrants at $2.05

Aptera Motors Corp. (Nasdaq: SEV) said on November 10, 2026 that it priced a registered direct offering of 3,428,571 Class B common shares at $1.75 each, alongside a concurrent private placement of warrants covering up to 3,428,571 more shares at a $2.05 exercise price. The company put aggregate gross proceeds at roughly $6 million before placement agent fees and offering expenses, with closing expected on or about November 11, 2026. Ladenburg Thalmann & Co. Inc. is lead placement agent and StoneX Financial Inc. is co-placement agent.

Context — why this Aptera raise matters now

Aptera framed the raise as funding for "general corporate purposes, ongoing product validation and manufacturing readiness activities," naming vehicle validation testing, design-for-manufacturability work, production planning, supplier engagements, and long-lead tooling among the intended uses. Those are pre-revenue line items. A company spending on tooling and supplier qualification before it ships vehicles is buying time on a production timeline, not funding an expansion of an existing business.

The size is the signal. Six million dollars is small against the cost of standing up vehicle manufacturing, which is why the structure matters more than the headline number. Aptera raised equity at $1.75 while attaching warrants struck 30 cents higher, at $2.05 — a 17.1% premium to the share price. That is a financing designed to bring in cash now and a second tranche only if the stock clears a higher bar later.

The report does not disclose Aptera's cash position, burn rate, or how long the net proceeds are expected to last. It also does not give a prior-period comparable, earlier guidance, or any stated funding target. Readers looking for a runway calculation will not find one in the announcement.

One structural condition stands out. The warrants are exercisable only on or after stockholder approval and carry a term of five and one half years from the initial exercise date. Until that approval arrives, the second tranche is contingent, not committed. Aptera's own risk disclosure flags this directly, warning that if approval fails the warrants never become exercisable and the company receives no exercise proceeds.

The placement agents are mid-tier specialists rather than bulge-bracket banks, which fits the deal size. Aptera describes itself as a public benefit corporation headquartered in Carlsbad, California.

Data — what the Aptera offering numbers show

The transaction splits into two instruments with different economics.

Item	Registered direct shares	Private placement warrants
Units	3,428,571	3,428,571
Price	$1.75 per share	$2.05 per share
Gross proceeds	~$6 million combined	Contingent on exercise
Status	Registered on Form S-3	Unregistered, Section 4(a)(2)/Reg D

Gross proceeds of roughly $6 million divide to about $1.75 per share across the registered tranche, meaning the headline figure is driven almost entirely by the share sale. Warrant proceeds are additional and conditional: exercising all 3,428,571 warrants at $2.05 would bring in roughly $7.03 million more, but only after stockholder approval and only if holders choose to exercise.

Before the deal, the registered shares and the warrant shares together represent 6,857,142 Class B shares. The report does not state Aptera's total shares outstanding, so the precise dilution percentage cannot be calculated from the disclosure. What can be said is that the warrant leg, if fully exercised, would add a second block of equity equal in size to the first.

The registration mechanics are standard. The shares are offered under a shelf registration statement on Form S-3 (File No. 333-299238), declared effective by the SEC on October 9, 2026. The warrants and underlying shares were not registered under the Securities Act and may not be offered or sold in the United States absent an effective registration statement or an applicable exemption. Aptera agreed to file a resale registration statement covering the warrant shares.

The report names no peer issuer and no sector index for comparison, and no market data on Aptera's share performance was provided.

Analysis — what $6 million at $1.75 signals for SEV holders

The pricing structure tells the story. A company confident of near-term re-rating would resist warrants; a company that needs cash and expects the stock to work higher over five and a half years would bundle them. The 17.1% exercise premium is the price Aptera paid for capital today.

The second-order effect lands on the shareholder register. Institutional investors buying the registered shares receive warrants on the same unit count, so their economic exposure to Aptera can double without a second negotiation. If the stock trades above $2.05 after approval, those holders face a straightforward decision to exercise or let the warrants expire. That creates a supply overhang above the strike.

The counter-argument deserves weight. A $6 million gross raise is modest, and after placement agent fees and estimated offering expenses the net figure is smaller still — the report does not quantify either deduction. If tooling and supplier engagement costs run ahead of plan, this raise may not be the last. Serial small raises at declining prices are the classic dilution path for pre-revenue manufacturers, and nothing in the disclosure rules that out.

Stockholder approval is the hinge. It converts a contingent warrant from optionality into a funded second tranche, and it is the single event most likely to change the company's cash position. Aptera's forward-looking statements list the failure to obtain that approval as an explicit risk.

Positioning is asymmetric. Warrant holders are effectively long a $2.05 call they received alongside their shares. Existing holders who did not participate absorbed dilution at $1.75 without receiving the offsetting warrant. Where the flow goes depends on whether the resale registration statement lands before the warrants become exercisable.

Outlook — what to watch after the Aptera offering

Three dates and conditions anchor the next phase. Closing is expected on or about November 11, 2026, subject to customary closing conditions. Stockholder approval for warrant exercisability must follow before any warrant proceeds are possible. And Aptera has committed to filing a resale registration statement covering the warrant shares, which the report does not date.

The prospectus supplement will be the next hard disclosure. It will be filed with the SEC and, once available, will carry the detailed terms that this announcement leaves out, including the net proceeds after fees. Aptera's Annual Report on Form 10-K for the year ended December 31, 2025 is cited as the venue for the broader risk factors.

The report names no price levels, moving averages, or technical thresholds, and no market data on SEV was provided. The only levels that exist in the disclosure are the deal's own: $1.75 for the registered shares and $2.05 for the warrants. Whether SEV trades above the strike after approval determines if the second tranche funds.

Frequently Asked Questions

What does the Aptera offering mean for existing SEV shareholders?

Existing holders who did not participate see their ownership stake diluted by 3,428,571 newly issued Class B shares at $1.75. They do not receive the warrants, which went to the institutional investors. The report does not state total shares outstanding, so the exact percentage of dilution cannot be computed from the disclosure alone.

What happens if Aptera stockholders reject the warrant approval?

Aptera's own risk disclosure addresses this. If stockholder approval is not obtained, the warrants never become exercisable and the company receives no proceeds from their exercise. The roughly $6 million gross from the registered share sale is unaffected, but the contingent second tranche of up to 3,428,571 shares at $2.05 disappears.